Castle Biosciences Inc Reports Q2 2024 Earnings
Castle Biosciences, Inc. Reports Q2 2024 Earnings
Overview: Castle Biosciences, Inc. (CSTL) reported its financial results for the quarter ended June 30, 2024.
Key Financial Metrics:
Metric | Q2 2024 | Q1 2024 | Q2 2023 | YoY Change | QoQ Change | Consensus Estimate | Comparison to Consensus |
---|---|---|---|---|---|---|---|
Total Revenue | $87.0M | $73.0M | $50.1M | +73.5% | +19.2% | $69.34M | +25.4% |
Earnings Per Share (EPS) | -$0.20 | -$0.30 | -$0.40 | +50% | +33.3% | -$0.27 | +25.9% |
Interpretation: Castle Biosciences reported strong financial performance this quarter with a substantial 73.5% year-over-year increase in total revenue. The company managed to outperform Wall Street consensus estimates significantly, indicating robust operational execution and market acceptance. EPS improved both year-over-year and quarter-over-quarter, although still reporting a loss.
Segment Revenue Performance:
Segment | Q2 2024 Revenue | Q2 2023 Revenue |
---|---|---|
Dermatologic Tests | $68.8M | $43.0M |
Non-Dermatologic Tests | $18.2M | $7.1M |
Interpretation: The dermatologic segment remains the primary revenue driver, with a revenue contribution of $68.8 million, representing a substantial increase from the same quarter last year. The non-dermatologic segment, although smaller, showed impressive growth, indicating successful market penetration and diversification.
Stock Price Movement: Following the earnings release, Castle Biosciences' stock price decreased by 1.93%.
Conclusion: Castle Biosciences exhibited strong performance across key metrics for Q2 2024, with significant revenue growth driven by both dermatologic and non-dermatologic segments. The company also outperformed consensus estimates in both revenue and EPS, reflecting effective operational strategies. However, the stock price saw a slight decline post-earnings announcement.
Impressive Revenue Growth in Third Quarter 2024 51Talk Q3 2024 Earnings Report51Talk Online Educat
Costco Wholesale Corporation Reports First Quarter Financial Results
Quanex Building Products Corporation Reports Q4 and Fiscal 2024 Financial Results
Share